Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Epilepsy Personal Assistant Device-A Mobile Platform for Brain State, Dense Behavioral and Physiology Tracking and Controlling Adaptive Stimulation

T. Pal Attia, D. Crepeau, V. Kremen, M. Nasseri, H. Guragain, SW. Steele, V. Sladky, P. Nejedly, F. Mivalt, JA. Herron, M. Stead, T. Denison, GA. Worrell, BH. Brinkmann

. 2021 ; 12 (-) : 704170. [pub] 20210729

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc21024279

Epilepsy is one of the most common neurological disorders, and it affects almost 1% of the population worldwide. Many people living with epilepsy continue to have seizures despite anti-epileptic medication therapy, surgical treatments, and neuromodulation therapy. The unpredictability of seizures is one of the most disabling aspects of epilepsy. Furthermore, epilepsy is associated with sleep, cognitive, and psychiatric comorbidities, which significantly impact the quality of life. Seizure predictions could potentially be used to adjust neuromodulation therapy to prevent the onset of a seizure and empower patients to avoid sensitive activities during high-risk periods. Long-term objective data is needed to provide a clearer view of brain electrical activity and an objective measure of the efficacy of therapeutic measures for optimal epilepsy care. While neuromodulation devices offer the potential for acquiring long-term data, available devices provide very little information regarding brain activity and therapy effectiveness. Also, seizure diaries kept by patients or caregivers are subjective and have been shown to be unreliable, in particular for patients with memory-impairing seizures. This paper describes the design, architecture, and development of the Mayo Epilepsy Personal Assistant Device (EPAD). The EPAD has bi-directional connectivity to the implanted investigational Medtronic Summit RC+STM device to implement intracranial EEG and physiological monitoring, processing, and control of the overall system and wearable devices streaming physiological time-series signals. In order to mitigate risk and comply with regulatory requirements, we developed a Quality Management System (QMS) to define the development process of the EPAD system, including Risk Analysis, Verification, Validation, and protocol mitigations. Extensive verification and validation testing were performed on thirteen canines and benchtop systems. The system is now under a first-in-human trial as part of the US FDA Investigational Device Exemption given in 2018 to study modulated responsive and predictive stimulation using the Mayo EPAD system and investigational Medtronic Summit RC+STM in ten patients with non-resectable dominant or bilateral mesial temporal lobe epilepsy. The EPAD system coupled with an implanted device capable of EEG telemetry represents a next-generation solution to optimizing neuromodulation therapy.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21024279
003      
CZ-PrNML
005      
20211013134004.0
007      
ta
008      
211006s2021 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3389/fneur.2021.704170 $2 doi
035    __
$a (PubMed)34393981
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Pal Attia, Tal $u Bioelectronics Neurophysiology and Engineering Laboratory, Department of Neurology, Mayo Clinic, Rochester, MN, United States
245    10
$a Epilepsy Personal Assistant Device-A Mobile Platform for Brain State, Dense Behavioral and Physiology Tracking and Controlling Adaptive Stimulation / $c T. Pal Attia, D. Crepeau, V. Kremen, M. Nasseri, H. Guragain, SW. Steele, V. Sladky, P. Nejedly, F. Mivalt, JA. Herron, M. Stead, T. Denison, GA. Worrell, BH. Brinkmann
520    9_
$a Epilepsy is one of the most common neurological disorders, and it affects almost 1% of the population worldwide. Many people living with epilepsy continue to have seizures despite anti-epileptic medication therapy, surgical treatments, and neuromodulation therapy. The unpredictability of seizures is one of the most disabling aspects of epilepsy. Furthermore, epilepsy is associated with sleep, cognitive, and psychiatric comorbidities, which significantly impact the quality of life. Seizure predictions could potentially be used to adjust neuromodulation therapy to prevent the onset of a seizure and empower patients to avoid sensitive activities during high-risk periods. Long-term objective data is needed to provide a clearer view of brain electrical activity and an objective measure of the efficacy of therapeutic measures for optimal epilepsy care. While neuromodulation devices offer the potential for acquiring long-term data, available devices provide very little information regarding brain activity and therapy effectiveness. Also, seizure diaries kept by patients or caregivers are subjective and have been shown to be unreliable, in particular for patients with memory-impairing seizures. This paper describes the design, architecture, and development of the Mayo Epilepsy Personal Assistant Device (EPAD). The EPAD has bi-directional connectivity to the implanted investigational Medtronic Summit RC+STM device to implement intracranial EEG and physiological monitoring, processing, and control of the overall system and wearable devices streaming physiological time-series signals. In order to mitigate risk and comply with regulatory requirements, we developed a Quality Management System (QMS) to define the development process of the EPAD system, including Risk Analysis, Verification, Validation, and protocol mitigations. Extensive verification and validation testing were performed on thirteen canines and benchtop systems. The system is now under a first-in-human trial as part of the US FDA Investigational Device Exemption given in 2018 to study modulated responsive and predictive stimulation using the Mayo EPAD system and investigational Medtronic Summit RC+STM in ten patients with non-resectable dominant or bilateral mesial temporal lobe epilepsy. The EPAD system coupled with an implanted device capable of EEG telemetry represents a next-generation solution to optimizing neuromodulation therapy.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Crepeau, Daniel $u Bioelectronics Neurophysiology and Engineering Laboratory, Department of Neurology, Mayo Clinic, Rochester, MN, United States
700    1_
$a Kremen, Vaclav $u Bioelectronics Neurophysiology and Engineering Laboratory, Department of Neurology, Mayo Clinic, Rochester, MN, United States $u Cognitive Systems and Neurosciences, Czech Institute of Informatics, Robotics and Cybernetics, Czech Technical University in Prague, Prague, Czechia $u Department of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, MN, United States
700    1_
$a Nasseri, Mona $u Bioelectronics Neurophysiology and Engineering Laboratory, Department of Neurology, Mayo Clinic, Rochester, MN, United States $u School of Engineering, University of North Florida, Jacksonville, FL, United States
700    1_
$a Guragain, Hari $u Bioelectronics Neurophysiology and Engineering Laboratory, Department of Neurology, Mayo Clinic, Rochester, MN, United States
700    1_
$a Steele, Steven W $u Division of Engineering, Mayo Clinic, Rochester, MN, United States
700    1_
$a Sladky, Vladimir $u Bioelectronics Neurophysiology and Engineering Laboratory, Department of Neurology, Mayo Clinic, Rochester, MN, United States $u Faculty of Biomedical Engineering, Czech Technical University in Prague, Kladno, Czechia
700    1_
$a Nejedly, Petr $u Bioelectronics Neurophysiology and Engineering Laboratory, Department of Neurology, Mayo Clinic, Rochester, MN, United States
700    1_
$a Mivalt, Filip $u Bioelectronics Neurophysiology and Engineering Laboratory, Department of Neurology, Mayo Clinic, Rochester, MN, United States
700    1_
$a Herron, Jeffrey A $u Department of Neurological Surgery, University of Washington, Seattle, WA, United States
700    1_
$a Stead, Matt $u Bioelectronics Neurophysiology and Engineering Laboratory, Department of Neurology, Mayo Clinic, Rochester, MN, United States $u Department of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, MN, United States
700    1_
$a Denison, Timothy $u Engineering Sciences and Clinical Neurosciences, Oxford University, Oxford, United Kingdom
700    1_
$a Worrell, Gregory A $u Bioelectronics Neurophysiology and Engineering Laboratory, Department of Neurology, Mayo Clinic, Rochester, MN, United States $u Department of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, MN, United States
700    1_
$a Brinkmann, Benjamin H $u Bioelectronics Neurophysiology and Engineering Laboratory, Department of Neurology, Mayo Clinic, Rochester, MN, United States $u Department of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, MN, United States
773    0_
$w MED00174552 $t Frontiers in neurology $x 1664-2295 $g Roč. 12, č. - (2021), s. 704170
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34393981 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20211006 $b ABA008
991    __
$a 20211013134001 $b ABA008
999    __
$a ind $b bmc $g 1708260 $s 1144776
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 12 $c - $d 704170 $e 20210729 $i 1664-2295 $m Frontiers in neurology $n Front. neurol. $x MED00174552
LZP    __
$a Pubmed-20211006

Najít záznam

Citační ukazatele

Možnosti archivace